BIOINEQUIVALENCE AND DRUG TOXICITY - HOW GREAT IS THE PROBLEM AND WHAT CAN BE DONE

被引:25
作者
GLEITER, CH
GUNDERTREMY, U
机构
[1] Abteilung Klinische Pharmakologie, Zentrum für Pharmakologie und Toxikologie, Universität Göttingen, D-37075
关键词
D O I
10.2165/00002018-199411010-00001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
[No abstract available]
引用
收藏
页码:1 / 6
页数:6
相关论文
共 32 条
[1]  
Schwabe U., Zur Frage der Bioäquivalenz von Generika, Internist, 29, (1988)
[2]  
Strom B., Generic drug substitution revisited, N Engl J Med, 316, (1987)
[3]  
Notes for guidance: Investigation of bioavailability and bioequivalence, The rules governing medicinal products in the European Community, 3, (1991)
[4]  
Bioavailability and bioequivalence requirements, 42, (1977)
[5]  
Ostroff R.B., Docherty J.P., Tricyclics, bioequivalence, and clinical response, Am J Psychiatry, 135, (1978)
[6]  
Weddington W.J., More on bioequivalence of tricyclics, Am J Psychiatry, 136, (1979)
[7]  
Sachdeo R., Belendiuk G., Generic vs. branded carbamazepine, Lancet, 1, (1987)
[8]  
Busch R.L., Generic carbamazepine and erythema multiforme: generic drug nonequivalency, N Engl J Med, 321, (1989)
[9]  
Locniskar A., Greenblatt D.J., Harmatz J.S., Et al., Bioinequivalence of a generic brand of diazepam, Biopharmaceut Drug Dispos, 10, pp. 597-605, (1989)
[10]  
Danon A., Horowitz J., Ben-Zvi Z., An outbreak of digoxin intoxication, Clin Pharmacol Ther, 21, (1977)